Aims: Hyperandrogenism, although mostly due to polygenic interactions, is monogenic for some enzymatic adrenal deficiencies. This study evaluates mono- and biallelic 21-hydroxylase deficiency (21OHD)-related hyperandrogenism in pediatric patients. Sensitizing and protective polymorphisms were investigated in carriers and cryptic forms of 21OHD. Methods: The study involved a monogenic analysis of CYP21A2 in patients (375 nonclassical 21OHD [NC21OHD] children; 306 hyperandrogenic 21OHD carriers, n = 306) and a polygenic association study (CAPN10-UCSNP44, PON1-108, TNFR2-M196R, IGF2-ApaI and IRS1-G972R polymorphisms) of 170 hyperandrogenic carriers plus 277 family members (control groups). The metabolic marker 17OH progesterone defined the degree of deficiency; clinical expressivity was determined by pediatric endocrinologists. Results: The group of 21OHD carriers manifesting hyperandrogenism was enriched in the CAPN-UCSNP44 rare variant in homozygosity (4.9 vs. 0.4%, NCBI data for the general population; p = 0.004). In our patients and controls, contrasting distributions were observed for this and another polymorphism, TNFR2-196R. In a recessive model, their rare variants were more frequently detected among the forms with high (p = 0.048) and low (p = 0.034) expressivity respectively. Conclusions: 21OHD-related pediatric hyperandrogenism follows monogenic and polygenic models. The opposite behaviors in terms of clinical expressivity detected for CAPN-UCSNP44 and TNFR2-M196R rare variants suggest these variants to be sensitizing and protective factors respectively in adrenal hyperandrogenism.

1.
Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss JF 3rd, Spielman RS, Dunaif A: Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 1999;96:8573–8578.
2.
Escobar-Morreale HF, Luque-Ramirez M, San Millan JL: The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005;26:251–282.
3.
Peral B, San Millan JL, Castello R, Moghetti P, Escobar-Morreale HF: Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab 2002;87:3977–3983.
4.
Witchel SF, Smith R, Tomboc M, Aston CE: Candidate gene analysis in premature pubarche and adolescent hyperandrogenism. Fertil Steril 2001;75:724–730.
5.
Mifsud A, Ramirez S, Yong EL: Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab 2000;85:3484–3488.
6.
White PC, Speiser PW: Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. Endocr Rev 2000;21:245–291.
7.
Speiser PW, White PC: Congenital adrenal hyperplasia. N Engl J Med 2003;349, 776–788.
8.
New MI: Nonclassic 21-hydroxylase deficiency. Fertil Steril 2006;86(suppl 1):S2.
9.
Ezquieta B, Ruano MLF, Dulin E, Arnao DR, Rodriguez A: Prevalence of frequent recessive diseases in the Spanish population through DNA analyses on samples from the neonatal screening. Med Clin (Barc) 2005;125:493–495.
10.
Levo A, Jaäskelainen J, Sistonen P, Siren MK, Voutilainene R, Partanen J: Tracing past population migrations: genealogy of steroid 21-hydroxylase (CYP21) mutations in Finland. Eur J Hum Genet 1999;7:188–196.
11.
Ezquieta B, Cueva E, Oyarzabal M, Oliver A, Varela J, Jariego C: Gene conversion (655 splicing mutation) and the founder effect (Q318X) contribute to the most frequent severe point mutations in congenital adrenal hyperplasia in the Spanish population. Clin Genet 2002;62:181–188.
12.
Moran C, Azziz R: 21-Hydroxylase-deficient nonclassic adrenal hyperplasia: the great pretender. Semin Reprod Med 2003;21:295–300.
13.
Carmina E, Rosato F, Janni A, Rizzo M, Longo RA: Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006;91:2–6.
14.
Kamel N, Tonyukuk V, Emral R, Corapcioglu D, Bastemir M, Gullu S: The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia. Endocr J 2003;50:815–823.
15.
Knochenhauer ES, Cortet-Rudelli C, Cunnigham RD, Conway-Myers BA, Dewailly D, Azziz R: Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. J Clin Endocrinol Metab 1997;82:479–485.
16.
Admoni O, Israel S, Lavi I, Gur M, Tenenbaum-Rakover Y: Hyperandrogenic carriers of CYP21 mutations: the role of genotype. Clin Endocrinol (Oxf) 2006;64:645–651.
17.
Ezquieta B, Cueva E, Varela J, Oliver A, Fernandez J, Jariego C: Non-classical 21-hydroxylase deficiency in children: association of adrenocorticotropic hormone-stimulated 17-hydroxyprogesterone with the risk of compound heterozygosity with severe mutations. Acta Paediatr 2002;91:892–898.
18.
Seminara SB, Crowley WF Jr: Genetic approaches to unraveling reproductive disorders: examples of bedside to bench research in the genomic era. Endocr Rev 2002;23:382–392.
19.
Bachega TASS, Billerbeck AEC, Marcondes JAM, Madureira G, Arnhold IJP, Mendonca BB: Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 2000;52:601–607.
20.
Nimkarn S, Cerame BI, Wei JQ, Dumic M, Zunec R, Brkljacic L, Skrabic V, New MI, Wilson RC: Congenital adrenal hyperplasia (21-hydroxylase deficiency) without demonstrable genetic mutations. J Clin Endocrinol Metab 1999;84:378–381.
21.
Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist. Stanford, Stanford University Press, 1959.
22.
Ezquieta B, Oliver A, Gracia R, Gancedo PG: Analysis of steroid 21-hydroxylase mutations in the Spanish population. Hum Genet 1995;96:198–204.
23.
Ezquieta B, Varela JM, Jariego C, Oliver A, Gracia R: Nonisotopic detection of point mutations in CYP21B gene in steroid 21-hydroxylase deficiency. Clin Chem 1996;42:1108–1110.
24.
Ezquieta B, Beneyto M, Munoz-Pacheco R, Barrio R, Oyarzabal M, Lechuga JL, Luzuriaga C, Hermoso F, Quinteiro S, Martinez S: Gene duplications in 21-hydroxylase deficiency: the importance of accurate molecular diagnosis in carrier detection and prenatal diagnosis. Prenat Diagn 2006;26:1172– 1178.
25.
Ezquieta B, Oyarzábal M, Jariego CM., Varela JM, Chueca M: A novel frameshift in the first exon of the 21-OH gene found in homozygosity in an apparently nonconsanguineous family. Horm Res 1999;51:135–141.
26.
Bernal C, Fernandez C, Martinez S, Ezquieta B: Premature androgenetic alopecia in adult male with nonclassic 21-OH deficiency. A novel nonsense CYP21A2 mutation (Y336X) in 2 affected siblings. Med Clin (Barc) 2006;127:617–621.
27.
Ezquieta B, Jariego CM, Varela JM, Oliver A, Gracia R: Microsatellite typing in the indirect analysis of steroid 21-hydroxylase gene. Prenat Diagn 1997;17:429–434.
28.
Gonzalez A, Abril E, Roca A, Aragon MJ, Figueroa MJ, Velarde P, Ruiz R, Fayez O, Galan JJ, Herreros JA, Real LM, Ruiz A: Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. J Clin Endocrinol Metab 2003;88:5529–5536.
29.
Ibanez L, Marcos MV, Potau N, White C, Aston CE, Witchel SF: Increased frequency of the G972R variant of the insulin receptor substrate-1 (IRS-1) gene among girls with a history of precocious pubarche. Fertil Steril 2002;78:1288–1293.
30.
Jensen DP, Urhammer SA, Eiberg H, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O: Variation in CAPN10 in relation to type 2 diabetes, obesity and quantitative metabolic traits: studies in 6018 whites. Mol Genet Metab 2006;89:360–367.
31.
Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu Y, Otsuka T, Sawabe T, Harashima S, Nagasawa K, Niho Y: Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 2001;44:2819–2827.
32.
Ezquieta B, Alonso M, Arnao MDR, Alvarez E, Rodríguez A, Siguero JPL: Should 21-hydroxylase deficiency genotyping be considered in assisted reproductive technology programs? Fertil Steril 2007;88:1437.e5–e11.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.